Sai Life Sciences Limited has announced a key leadership transition in its senior management team, appointing Dr. John Pavey as Senior Management Personnel effective 1 April 2026. The appointment was disclosed to stock exchanges on 30 March 2026 under Regulation 30 of SEBI Listing Regulations.

Leadership Transition Details

The company has structured a seamless transition in its Global PR&D leadership. Dr. Pavey will assume the role of Head – Global PR&D, replacing Dr. Dean David Edney, who will retire from his position as Senior Management Personnel at the close of business on 31 March 2026.

Professional Background and Expertise

Dr. Pavey brings extensive global experience to his new role, with over two decades of expertise in CMC and chemical development. His career includes senior leadership positions at prominent pharmaceutical companies including Johnson & Johnson, UCB, and AstraZeneca.

His professional expertise encompasses:

• API development across the product lifecycle
• Regulatory approvals and commercial supply
• New modalities and digital chemistry
• Sustainable manufacturing practices
• Quality by Design methodologies

Academic Credentials

Dr. Pavey's academic background reflects strong foundations in chemistry and research. His educational qualifications include a BA (Hons) in Chemistry from the University of Oxford and a PhD in Organic Chemistry from the University of Liverpool. He has also completed postdoctoral research at the University of Cambridge.

Regulatory Compliance

The appointment disclosure was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/0155 dated 11 November 2024. Company Secretary & Compliance Officer Runa Karan signed the regulatory filing on behalf of the company.

Sai Life Sciences Limited has completed the allotment of 11,100 fully paid-up equity shares under its Employees Stock Option Plan 2008 (ESOP 2008) scheme. The Board of Directors approved this allotment through a circular resolution dated 24 March 2026, as part of the company's employee incentive program.

Share Allotment Details

The allotment represents the exercise of stock options by employees under the ESOP 2008 scheme. The shares were issued at an exercise price of Rs. 188.90 per share, with a premium of Rs. 187.90 per share over the par value of Re. 1.

Share Capital Impact

Following this allotment, the company's share capital structure has been updated. The shares were issued in dematerialized form under ISIN INE570L01029, with distinctive numbers ranging from 211768135 to 211779234.

ESOP 2008 Scheme Overview

The Employees Stock Option Plan 2008 is designed to attract, retain, and reward employees while contributing to the company's growth. The scheme features:

• Maximum vesting period of 5 years with multiple vesting options
• Exercise period extending until the employee remains in service
• Pricing determined by the Nomination and Remuneration Committee in compliance with applicable accounting standards and SEBI regulations

Regulatory Compliance

The allotment was conducted in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company has filed the necessary disclosures with both BSE Limited and National Stock Exchange of India Limited, where its shares are listed.

The shares issued are identical to existing equity shares in all respects, with no lock-in restrictions applicable. This allotment demonstrates the company's commitment to employee participation in its growth through equity-based compensation programs.